Therapy Area Market Access Lead, Hematology (EMEA), Janssen

Clare Hague is the Therapy Area Market Access Leader for Hematology (EMEA Region) at Janssen (a Johnson & Johnson company). She has worked within the pharmaceutical industry for the past 14 years in market access positions, focused on ensuring timely patient access to innovative cancer medicines, including cell & gene therapies. Since 2015, Clare has been an honorary lecturer and academic supervisor in health technology assessment at the Department of Health Sciences & Medicine at the University of Lucerne, Switzerland.
Before joining the pharmaceutical industry, Clare spent 4 years as an MRC Senior Research Fellow at the University of Sheffield. From 1999-2007, she was one of the Principal Investigators of the National Coordinating Centre for Health Technology Assessment funded RCT of Extracorporeal membrane oxygenation for adults with severe, but potentially reversible respiratory failure in collaboration with Glenfield Hospital, the London School of Hygiene & Tropical Medicine and the Universities of Leicester & East Anglia. Between 2001-2004, she developed a case-mix adjusted reimbursement system for adult critical care that formed the basis of the UK’s Healthcare Resource Group (HRG) system that was adopted by the Department of Health for routine use in 2004.
Between 1995-2002, Clare worked in the NHS, where she was the co-founder and Director of a research charity – the Medical Economics & Research Centre, Sheffield (MERCS) which undertook research projects to further knowledge and understanding of the costs and cost-effectiveness of critical care resources. Clare has a PhD in Health Services Research, a BA (Hons) in International Business and is currently undertaking a LLM in Healthcare Ethics & Law at the University of Manchester. She has published over 65 papers in peer-reviewed journals.



7 October 2021